Samsung Biologics announced a CHF 1.46 billion USD 1.8 billion public tender offer to acquire Switzerland-based PolyPeptide Group, marking the CDMO's entry into peptide therapeutics. The deal extends its capabilities beyond antibodies and antibody-drug conjugates, adds manufacturing sites in India,…
Samsung Biologics announced a CHF 1.46 billion USD 1.8 billion public tender offer to acquire Switzerland-based PolyPeptide Group. The deal marks the contract development and manufacturing organisation's entry into peptide therapeutics, moving it beyond the antibody and antibody-drug conjugate ADC manufacturing that anchors its existing business.
The target is a peer in the CDMO space. PolyPeptide Group, listed on the SIX Swiss Exchange, is a Switzerland-based contract manufacturer whose existing clients, contracts, and manufacturing sites will flow into the enlarged group if the deal completes. Peptide therapeutics are a rapidly expanding segment of the biopharmaceutical market, covering treatments for diseases, hormone regulation, and targeted biological functions, and the acquisition gives Samsung Biologics a peptide synthesis platform and a manufacturing footprint in India, the US, and Europe at one stroke.
Samsung Biologics describes the transaction as expected to enhance its operational capabilities, diversify its service offering, and strengthen that geographic footprint. The integration will be complete, not partial. After the acquisition closes, Samsung Biologics plans to squeeze out remaining minority shareholders and delist PolyPeptide from the SIX Swiss Exchange, making it a wholly owned subsidiary.
The CHF 1.46 billion price, roughly USD 1.8 billion, will be delivered through a public tender offer, giving PolyPeptide shareholders a defined window to sell their shares. The planned squeeze-out after completion is the standard Swiss mechanism for buying out minority holders once the majority threshold is reached, clearing the path to full ownership and delisting.
The advisory lineup reflects the two legal systems involved. JPMorgan served as exclusive financial adviser to Samsung Biologics, and Ernst & Young Han Young acted as accounting and tax adviser. O'Melveny & Myers and Schellenberg Wittmer advised Samsung Biologics on the deal, with Schellenberg Wittmer providing Swiss law advice. Daniel Kim, partner at O'Melveny & Myers, led the advisory team for Samsung Biologics.
PolyPeptide Group was advised separately. Homburger acted as legal counsel to the company, with Frank Gerhard, partner at Homburger, leading its legal counsel team.
The timetable is conditional rather than fixed. Samsung Biologics expects the tender offer to launch by the end of August and the acquisition to complete by the end of the year, subject to customary offer conditions and regulatory approvals. That schedule may change if conditions are not met or approvals are delayed, which makes the stated dates targets rather than commitments.
Samsung Biologics is a contract development and manufacturing organisation CDMO for pharmaceutical products, best known for cell culture production of antibodies and ADCs at commercial scale. PolyPeptide Group is a Switzerland-based peer company in the CDMO space, but its manufacturing discipline is different: peptides are built by chemical synthesis, not grown in living cells. That difference is the strategic logic of the deal.
For Samsung Biologics, the acquisition extends capabilities beyond antibodies and ADCs into peptide therapeutics. The service offering becomes broader, and the buyer gains a technology platform that would take years to replicate internally. For PolyPeptide's clients, the change of ownership brings a parent with deep experience in large-scale biologics manufacturing and the balance sheet to invest in capacity.
The acquisition also strengthens the buyer's geographic footprint in India, the US, and Europe, regions where PolyPeptide operates manufacturing sites. For a CDMO, geography is a form of redundancy: multi-site production protects clients from single-site failure and can place manufacturing closer to the clinical trial sites and markets that the products serve.
Peptides occupy a middle ground between small molecules and large biologics. They are short chains of amino acids, from a few residues to several dozen, and their biological information is carried by the sequence of those residues and the shape the chain folds into. Cell surface receptors recognise that shape, and binding triggers or blocks the signalling pathways that control physiology.
That is why peptide therapeutics are described as a rapidly expanding segment of the biopharmaceutical market, covering treatments for diseases, hormone regulation, and targeted biological functions. Hormone regulation is the most direct example: many native hormones are peptides, and synthetic versions can restore, amplify, or suppress those signals. Beyond endocrinology, peptide drugs can be designed to act on other receptors, adding selectivity because the molecules are large enough to recognise specific surface structures yet small enough to be synthesised chemically rather than cultured in bioreactors.
The therapeutic activity depends on precise sequence and purity. Introduce a single wrong amino acid, an incomplete chain, or a side reaction product, and a peptide drug can lose potency or gain toxicity. Quality is not a manufacturing detail; it is the determinant of clinical outcome. This is precisely why manufacturing capacity has become the pressure point for the field.
Antibodies are grown, not built. They are produced by engineered mammalian cell lines in large bioreactors, a process built on cell biology: transfection, selection, culture, harvest, and purification of large proteins with complex glycosylation. Peptides follow a different path. They are assembled chemically, usually by solid-phase synthesis, in which the growing chain is anchored to a resin and amino acids are added one by one in repeating cycles of coupling and deprotection.
Each cycle adds another residue but also another opportunity for side reactions, incomplete coupling, and racemisation. Yield losses accumulate with chain length, so longer peptides become progressively harder to make at commercial scale. The impurities that form, deletion sequences, epimers, oxidised residues, closely resemble the desired product and are difficult to remove by chromatography. Peptide solubility and aggregation further complicate synthesis, purification, and formulation.
This is where the deal's logic sits. Samsung Biologics brings large-scale manufacturing infrastructure and experience running GMP facilities at commercial volume. PolyPeptide brings peptide synthesis expertise that takes years to build. The acquisition signals significant investment in peptide manufacturing capacity by a major biologics CDMO, and it has the potential to alleviate supply bottlenecks for peptide-based therapeutics. If the combined operation works as intended, the result could be faster movement of peptide drugs from clinical development into commercial production, which is the point where demand for contract manufacturing typically peaks.
For researchers, the immediate question is capacity. Peptide programs in clinical development need a contract manufacturing partner that can scale from grams for toxicology studies to kilograms for late-stage trials and commercial supply. Supply bottlenecks for peptide-based therapeutics have been a recurring constraint, and a major biologics CDMO entering the space increases the number of credible partners for academic groups and small companies seeking reliable contract manufacturing partners.
For clinicians, the relevance is indirect but real. Peptide drugs depend on manufacturing consistency, because the active product is the chemical entity itself, a defined chain of amino acids. Reliable supply at consistent quality is what allows a clinic to depend on a therapy for chronic use. Consolidation under a parent with established quality systems and commercial infrastructure can support that reliability, provided the integration is managed without disrupting existing supply agreements.
For the supply chain, the deal concentrates more peptide capacity under one owner. Samsung Biologics gains sites in India, the US, and Europe, a geographic spread that can protect clients from regional disruption. But integration also carries risk. PolyPeptide's existing contracts, clients, and manufacturing sites will be absorbed into a much larger organisation, and how those commitments are honoured will determine whether the deal creates new capacity or simply redistributes what already exists.
The announcement establishes the structure of the deal, not its outcome. The transaction is subject to customary offer conditions and regulatory approvals, and the expected timeline may change if conditions are not met or approvals are delayed. The tender offer is expected to launch by the end of August and the acquisition to complete by the end of the year, but those dates are assumptions embedded in the announcement, not guarantees.
Three open questions define the uncertainty. First, what specific peptide products or manufacturing assets does PolyPeptide Group bring to Samsung Biologics? Neither company has disclosed the product portfolio or the capabilities that transfer with the sites. Second, will the required regulatory approvals be granted, and will the tender offer complete as scheduled? Cross-border manufacturing deals are reviewed by competition and foreign investment regulators, and the timetable depends on their pace of review.
Third, how will the acquisition affect PolyPeptide's existing contracts, clients, and manufacturing sites in India, the US, and Europe? CDMO relationships are built on long-term supply agreements and developed technical processes, and the value of the deal depends in part on those relationships surviving the change of ownership intact.
What would settle these questions is concrete and observable: the launch of the tender offer by the end of August, the clearance of the required approvals, and the completion of the acquisition by the end of the year. Beyond that, disclosure of the assets being acquired and of how PolyPeptide's client commitments will be managed during integration would tell researchers and clinicians whether this acquisition is an expansion of peptide manufacturing capacity or a consolidation of it. For now, the deal stands as a signal that peptide therapeutics have moved to the center of commercial strategy for one of the world's largest biologics manufacturers.
Related reading: Samsung Biologics makes bid to acquire peptide CDMO PolyPeptide, Peptide and Oligonucleotide CDMO Market to Hit USD 11.42 Billion by 2035, Samsung Biologics acquires PolyPeptide for $1.8 billion, Samsung Biologics Acquires Swiss CDMO for $1.8 Billion to Enter Obesity Drug Market.